Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

A person's 'bioenergetic age' -- or how youthfully their cells generate energy -- might be a key indicator of whether they're at risk of developing Alzheimer's disease, new research shows. The study ...

A person’s “bioenergetic age”, or how youthfully their cells generate energy, might be a key indicator of whether they’re at ...

Researchers have discovered that a person's "bioenergetic age," reflecting how efficiently cells produce energy, strongly predicts Alzheimer's risk and progression.

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...

Scientists have discovered that how well a person’s cells generate energy—what they call “bioenergetic age”—could be a strong ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, sales of lecanemab, known by ...

The Japanese pharma company – currently in the process of rolling out new amyloid-targeting Alzheimer's therapy Leqembi ...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Bioenergetic age, or how efficiently cells produce energy, could predict Alzheimer’s risk, with healthy lifestyle choices ...